Infliximab treatment reduces complement activation in patients with rheumatoid arthritis.
about
Comparative serum proteome expression of the steroid-induced femoral head osteonecrosis in adultsAntibodies against cyclic citrullinated peptide don't decrease after 6 months of infliximab treatment in refractory rheumatoid arthritis.Mode of function of biological anti-TNF agents in the treatment of inflammatory bowel diseases.Exposure to nuclear antigens contributes to the induction of humoral autoimmunity during tumour necrosis factor alpha blockade.Humoral and cellular monitoring to predict the development of infection in Crohn's disease patients beginning treatment with infliximab.Detrimental roles of TNF-alpha in the antiphospholipid syndrome and de novo synthesis of antiphospholipid antibodies induced by biopharmaceuticals against TNF-alpha.
P2860
Infliximab treatment reduces complement activation in patients with rheumatoid arthritis.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Infliximab treatment reduces complement activation in patients with rheumatoid arthritis.
@ast
Infliximab treatment reduces complement activation in patients with rheumatoid arthritis.
@en
type
label
Infliximab treatment reduces complement activation in patients with rheumatoid arthritis.
@ast
Infliximab treatment reduces complement activation in patients with rheumatoid arthritis.
@en
prefLabel
Infliximab treatment reduces complement activation in patients with rheumatoid arthritis.
@ast
Infliximab treatment reduces complement activation in patients with rheumatoid arthritis.
@en
P2093
P2860
P356
P1476
Infliximab treatment reduces complement activation in patients with rheumatoid arthritis.
@en
P2093
Dijkmans BA
Familian A
Voskuyl AE
van Mierlo GJ
P2860
P304
P356
10.1136/ARD.2004.029124
P407
P577
2005-07-01T00:00:00Z